13 results about "Prednisone" patented technology

Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

The present disclosure relates to the use of cortisol, cortisone, cortisone acetate, hydrocortisone, fludrocortisone, prednisolone, prednisone, methylprednisolone, Dehydroepiandrosterone (DHEA), dexamethasone, betamethasone, adrenocorticotropic hormone (ACTH), ganaxolone, tetracosactide or combinations thereof for preventing and / or reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP). The disclosure further provides pharmaceutical compositions and methods for preventing and / or reducing the risk of SUDEP, particularly in Dravet Syndrome patients.

The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).

This invention provides a strain of *Lactobacillus plantarum*, and discloses the fermentation product of *Eucommia ulmoides* leaves, *Rehmannia glutinosa*, dried ginger, and *Dendrobium officinale* obtained by fermenting these herbs, along with its preparation method and applications. This fermentation product can directionally activate the phenylpropane biosynthetic pathway, inducing the generation of characteristic small molecule metabolites of polyphenols, particularly sanguranyl sulfadiazine (SSA). Moreover, compared to the raw materials, the fermentation product contains more active small molecule metabolites. Finally, experiments on zebrafish modeled with prednisone demonstrated that the fermentation product can significantly promote bone formation. The fermentation product mainly restores the expression levels of related genes to normal zebrafish gene expression levels by regulating these genes. Therefore, the fermentation product can be used to prepare foods or medicines that improve bone health.

The invention provides a plant lactobacillus, and also discloses a secondary yellow fermented product obtained by fermenting eucommia ulmoides leaves, rehmannia, dried ginger and dendrobium officinale with the plant lactobacillus as well as a preparation method and application of the secondary yellow fermented product. The sec-yellow leavening can directionally activate a phenylpropane biosynthetic pathway and induce the generation of polyphenol characteristic small molecule metabolites, especially the generation of mulberry furan W. The invention also discloses a preparation method of the sec-yellow leavening. And compared with the raw materials, the fermented product has more active small molecule metabolites. Finally, zebra fish experiments after prednisone modeling prove that the sec-yellow yeast can significantly promote osteogenesis. The sec-yellow leavening is recovered to the normal zebrafish gene expression level mainly by regulating the related gene expression level. Therefore, the sec-yellow leavening can be applied to preparation of foods or medicines for improving bone health.

Methods and compositions are provided for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib, a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

The invention discloses a construction method and application of a rodent model for male adult offspring fertility reduction caused by prednisone exposure during pregnancy. The fertility of male adult offspring is reduced due to prednisone exposure during pregnancy, rodents are subjected to gavage with prednisone in the whole pregnancy process, and the offspring is normally fed for 12 weeks after being born. Male offspring testis or sperms which are 20 days after pregnancy and 12 weeks after birth are obtained, and fetal testis dysplasia and adult fertility reduction are proved. Based on the animal model, it is proved that male adult offspring fertility reduction caused by prednisone exposure during pregnancy can be reversed when genistein is given to pregnant rats at the same time during pregnancy. The animal model established by the invention has the characteristics of novelty, reliability, simplicity and convenience, and is of great significance to elucidating a fertility reduction mechanism of male offspring caused by prednisone exposure during pregnancy and exploring an early prevention and treatment technology of the male offspring.

The invention discloses a method for simultaneously improving the sensitivity and cross contamination resistance of a latex turbidimetric kit and application, and belongs to the technical field of biology. According to the method for simultaneously improving the sensitivity and the cross contamination resistance of the latex turbidimetric kit, latex microspheres used in a sensitization latex solution are low-mass-density latex microspheres, and the sensitization latex solution contains prednisone. According to the method disclosed by the invention, the sensitivity is improved by 39%-46%; meanwhile, after the reagent is subjected to cross contamination, the onboard service time is prolonged by 3-10 times, the scrapping time is prolonged from 2-3 days to 7-30 days for stabilization, and the basic use requirement is met.

The invention relates to a compound of formula:which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.

Described herein are methods for reducing an antibody response to uricase therapy, improving the treatment of gout, reducing uric acid levels, and preventing and / or delaying infusion reactions. The methods may include administration of a uricase and a steroid as described herein.

The use of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone in the preparation of a drug for treating peripheral T-cell lymphoma (PTCL). The PTCL is preferably treatment-naïve PTCL. Other first-line and second-line drugs for treating PTCL may also be further used on the basis of the foregoing. A method for treating PTCL, the method comprising administering, to a patient, a therapeutically effective amount of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone. The combined administration of the drugs is safe and tolerable, has a small toxicity and few side effects, and can obtain a higher total objective remission rate (ORR) in treatment-naïve PTCL patients.

The invention discloses a phenylbutazone peak shifting sustained release injection. Every 100 g of the phenylbutazone peak shifting sustained release injection is prepared from the following components by weight: 4.0 to 10.0 g of phenylbutazone, 3.0 to 9.0 g of polyethylene glycol 12000, 5.0 to 13.0 g of povidone C15, 8.0 to 18.0 g of ethyl oleate, 4.0 to 8.0 g of span 20, 1.0 to 3.0 g of behenic acid, 0.5 to 2.5 g of propylene glycol alginate, 0.1 to 2.0 g of propyl gallate and the balance of corn oil. The injection contains three kinds of phenylbutazone drug forms, the drug is released in different time periods after intramuscular injection, and the peak value of plasma concentration is staggered, so that the effect of staggered-peak release is realized. According to the technology, on one hand, the highest plasma concentration is reduced, the liver and kidney metabolism burden is remarkably relieved, and the safety is improved, on the other hand, the effective plasma concentration maintaining time is prolonged, the administration frequency is reduced, the stress reaction generated in the animal fixing process is reduced, and time and labor are saved. Meanwhile, the invention further discloses a preparation method, the process is easy to convert, and the application prospect is wide.